EGFR and colorectal cancer: EGFR is a well-characterized oncogene, and therapies targeting EGFR, from small-molecular inhibitors (e.g., gefitinib, erlotinib) to monoclonal antibodies (e.g., cetuximab), are currently approved by the United States Food and Drug Administration (FDA) as treatments for various cancers, including colorectal cancers, non-squamous cell lung cancers, and head and neck cancers [33], but not for any ovarian cancers.